Investigation of the tolerability of oral stevioside in Brazilian hyperlipidemic patients

Silva, Gisleine Elisa Cavalcante da; Assef, Abdol H.; Albino, Cláudio Cordeiro; Ferri, Leticia; Tasin, Gilson; Takahashi, Mirian Hideko; Filho, Wilson Eik; Bazotte, Roberto Barbosa

doi:10.1590/s1516-89132006000500007

Cited by 28 publications

(27 citation statements)

References 13 publications

(16 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No significant difference was observed in biochemistry parameters except glucose in high dose (Table 3). In addition, the obtained results were in accordance with those of the other studies that showed that oral stevioside was safe and supported the well-established tolerability during long-term uses as sweetener (12). Furthermore, in a In conclusion, the current study demonstrated that stevioside did not induce hepatotoxicity in the liver tissue by assessing the activities of SGOT, SGPT, and chemical parameters, as reported in previous studies.…”

Section: Discussionsupporting

confidence: 91%

Investigation of the Hepatic Effects of Stevioside on Chicken Embryo Method

Sadighara

Jahanbakhsh

Araghi

et al. 2017

Jundishapur J Nat Pharm Prod

View full text Add to dashboard Cite

Background: Stevioside is well known for its sweetness in food industries. The liver plays an important role in food metabolism and is susceptible to the toxicity from food and its metabolites. Objectives: The current study aimed at assessing stevioside hepatotoxicity in the chicken embryo model. Methods: Stevioside was injected on the day 4 of incubation of chickens. The fertile eggs were randomly divided into 4 groups: control (without injection), 10 ppm, 100 ppm, and 1000 ppm of stevioside. The livers and serum samples were collected on the day 20 of incubation. Oxidative stresses of organ, enzymatic activity, and serum biochemical parameters were evaluated. Results: The changes in the liver enzymes activity and biochemical parameters were not significant. There was no significant difference in glutathione (GSH) level, lipid peroxidation, and cupric assay; there was a decrease in the ferric reducing/antioxidant power (FRAP). Conclusions: There were no significant changes in liver enzymes activity and oxidative stress parameters of liver. It was concluded that stevioside did not cause marked damages in liver.

show abstract

Section: Discussionsupporting

confidence: 91%

Investigation of the Hepatic Effects of Stevioside on Chicken Embryo Method

Sadighara

Jahanbakhsh

Araghi

et al. 2017

Jundishapur J Nat Pharm Prod

View full text Add to dashboard Cite

show abstract

“…Commercially, the use of stevioside (as a sweetener) has been established in different countries of the world, such as Australia and Japan. Furthermore, the diverse pharmacological effects of stevioside such as antibacterial effects, anticaries effect, antiedema effects, antifungal effects, antihyperglycemic effects on rabbits, hypotensive effects, and hypoglycemic effects in human were confirmed by some animal and clinical trials [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Preliminary analysis of the effect of Stevia (Stevia rebaudiana) in patients with chronic kidney disease (stage I to stage III)

Rizwan

Rashid

Yesmine

et al. 2018

Contemporary Clinical Trials Communications

View full text Add to dashboard Cite

BackgroundStevia, Stevia rebaudiana (Bertoni), has become an important economic plant for its commercial use as a sweetener. Stevia plays a significant role in the healthcare practice of different cultures and in population. Previous animal and clinical studies demonstrated the efficacy of Stevia against chronic diseases like diabetes and hypertension. This study aimed to investigate the beneficial effect of Stevia in chronic kidney disease (CKD) patients after three (3) months of treatment along with the conventional antihypertensive and anti diabetic medications.MethodsA prospective, interventional, randomized, single-blind, placebo-controlled trial has been done with 97 participants. Stevia capsule (250 mg) or matching placebo was given to the participants twice daily along with Angiotensin-II Receptor Blocker (ARB) and/or Ca2+ Channel Blocker (CCB). First follow up visits were done after 3 months of the interval. Blood and urine samples were collected for the biochemical tests. A structured questionnaire was used for the baseline assessment. Informed consent was taken from each participant.ResultsBoth hypertension and diabetes were found to be associated with CKD. Most of the participants (52.3%) of Stevia group were in CKD Stage II. Significant changes were found in Serum creatinine (p < 0.027), Serum Uric acid (p < 0.009), Fasting blood sugar (p < 0.041) and Postprandial blood sugar (p < 0.013) and Microalbumin (p < 0.041) level in the treatment group.ConclusionThe initial result demonstrated that Stevia has the potential for a significant improvement of some biochemical parameters in CKD patients. After completion of the nine (9) months clinical trial, the constructive effect of Stevia can be confirmed in this group of patients.

show abstract

“…Administration of a crude steviol glycoside extract at doses up to 15 mg/kg bw/day for 24 weeks had no effect on blood pressure in patients with mild essential hypertension (12 males and 2 females divided equally between the placebo and treatment groups) (Ferri et al, 2006).…”

Section: Studies On Renal and Cardiovascular Effectsmentioning

confidence: 92%

Scientific Opinion on the safety of steviol glycosides for the proposed uses as a food additive

2010

EFS2

110

View full text Add to dashboard Cite

Steviol glycosides in the present evaluation are mixtures of steviol glycosides that comprise not less than 95% of stevioside and/or rebaudioside A. Stevioside as a sweetener was evaluated by the SCF in 1984, 1989 and 1999. JECFA reviewed the safety of steviol glycosides in 2000, 2005, 2006, 2007, and 2009 and established an ADI for steviol glycosides (expressed as steviol equivalents) of 4 mg/kg bw/day. The Panel considers that the results of toxicology studies on either stevioside or rebaudioside A are applicable for the safety assessment of steviol glycosides as both rebaudioside A and stevioside are metabolised and excreted by similar pathways, with steviol being the common metabolite for both. Considering the available toxicity data (in vitro and in vivo animal studies and some human tolerance studies), the Panel concludes that steviol glycosides, complying with JECFA specifications, are not carcinogenic, genotoxic or associated with any reproductive/developmental toxicity. The Panel establishes an ADI for steviol glycosides, expressed as steviol equivalents, of 4 mg/kg bw/day based on application of a 100‐fold uncertainty factor to the NOAEL in the 2‐year carcinogenicity study in the rat of 2.5% stevioside in the diet. This is equal to 967 mg stevioside/kg bw/day (corresponding to approximately 388 mg steviol equivalents/kg bw/day). Conservative estimates of steviol glycosides exposures both in adults and in children suggest that it is likely that the ADI would be exceeded at the maximum proposed use levels.

show abstract

Investigation of the tolerability of oral stevioside in Brazilian hyperlipidemic patients

Abstract: ABSTRACT

Cited by 28 publications

References 13 publications

Investigation of the Hepatic Effects of Stevioside on Chicken Embryo Method

Investigation of the Hepatic Effects of Stevioside on Chicken Embryo Method

Preliminary analysis of the effect of Stevia (Stevia rebaudiana) in patients with chronic kidney disease (stage I to stage III)

Scientific Opinion on the safety of steviol glycosides for the proposed uses as a food additive

Contact Info

Product

Resources

About